CD274 and neoplasm: In lung cancer and colorectal cancer, decitabine triggers tumor PD-L1 expression by inducing DNA hypomethylation, triggering an anticancer immune response, and remodeling the tumor microenvironment to improve the effect of PD-L1 immunotherapy (80, 81).